title: [Invasive disseminated aspergillosis in combined immunosuppressive therapy in systemic lupus erythematosus].
authors.forename: G
authors.initials: G
authors.lastname: Teuber
authors.forename: A
authors.initials: A
authors.lastname: Schwarting
authors.forename: P
authors.initials: P
authors.lastname: Mildenberger
authors.forename: G
authors.initials: G
authors.lastname: Schmidt-Brücken
authors.forename: R
authors.initials: R
authors.lastname: Moll
authors.forename: A
authors.initials: A
authors.lastname: Bornemann
authors.forename: E
authors.initials: E
authors.lastname: Wandel
authors.forename: R
authors.initials: R
authors.lastname: Wanitschke
authors.forename: K H
authors.initials: KH
authors.lastname: Meyer zum Büschenfelde
mesh_terms: D000368:Aged; D001228:Aspergillosis / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D003520:Cyclophosphamide / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D016469:Fungemia / Q000139:chemically induced / Q000276:immunology / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D008181:Lupus Nephritis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D009894:Opportunistic Infections / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D011239:Prednisolone / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone
vernacular_title: Invasive disseminierte Aspergillose unter kombinierter immunsuppressiver Therapie bei systemischem Lupus erythematodes.